Ayala Pharmaceuticals Inc Stock News

- Part A of AL102 RINGSIDE study fully enrolled; interim data expected mid-2022 – - Part A of AL102 RINGSIDE study fully enrolled; interim data expected mid-2022 –

Ayala Pharmaceuticals, Inc. (AYLA) delivered earnings and revenue surprises of 1.49% and 32.79%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the

AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of 0% and 99.94%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

REHOVOT, Israel and WILMINGTON, Del., March 09, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small

REHOVOT, Israel and WILMINGTON, Del., March 09, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small m

Asana's (ASAN) fourth-quarter results are likely to reflect benefits from expansion of its enterprise customer base.

Ayala Pharmaceuticals Inc (AYLA) shares closed 4.6% lower than its previous 52 week low, giving the company a market cap of $100M. The stock is currently down 15.3% year-to-date, down 42.8% over the past 12 months, and down 52.0% over the past five years. This week, the Dow Jones Industrial Average fell 1.3%, and the S&P 500 fell 2.6%. Trading Activity Trading volume this week was 49.9% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.6. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 734.0% The company's stock price performance over the past 12 months lags the peer average by 373.6% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Ayala Pharmaceuticals Inc (AYLA) shares closed 4.3% lower than its previous 52 week low, giving the company a market cap of $109M. The stock is currently down 7.3% year-to-date, down 38.6% over the past 12 months, and down 47.5% over the past five years. This week, the Dow Jones Industrial Average fell 0.5%, and the S&P 500 fell 1.7%. Trading Activity Trading volume this week was 27.3% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.6. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought.The stock closed at 11.5% lower than its 5-day moving average, 15.4% lower than its 20-day moving average, and 28.9% lower than its 90-day moving average. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -2544.4% The company's stock price performance over the past 12 months lags the peer average by 444.1% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Ayala Pharmaceuticals Inc (AYLA) shares closed today at 1.9% above its 52 week low of $7.74, giving the company a market cap of $118M. The stock is currently flat year-to-date, down 31.1% over the past 12 months, and down 43.4% over the past five years. This week, the Dow Jones Industrial Average fell 0.2%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 93.7% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.6. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -100.0% The company's stock price performance over the past 12 months lags the peer average by 304.0% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

REHOVOT, Israel and WILMINGTON, Del., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small mo

Zacks Investment Research downgraded shares of Ayala Pharmaceuticals (NASDAQ:AYLA) from a buy rating to a hold rating in a research report released on Tuesday morning, Zacks.com reports. According to Zacks, Ayala Pharmaceuticals Inc. is a clinical-stage oncology company. It focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. []

Zacks Investment Research downgraded shares of Ayala Pharmaceuticals (NASDAQ:AYLA) from a buy rating to a hold rating in a report published on Wednesday morning, Zacks.com reports. According to Zacks, Ayala Pharmaceuticals Inc. is a clinical-stage oncology company. It focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. Ayala []

Ayala Pharmaceuticals (NASDAQ:AYLA) was upgraded by Zacks Investment Research from a hold rating to a buy rating in a research report issued on Thursday, Zacks.com reports. The firm presently has a $10.00 target price on the stock. Zacks Investment Researchs price target indicates a potential upside of 13.51% from the stocks previous close. According to []

Ayala Pharmaceuticals (NASDAQ:AYLA) was upgraded by Zacks Investment Research from a hold rating to a buy rating in a research note issued to investors on Friday, Zacks.com reports. The brokerage currently has a $11.00 price target on the stock. Zacks Investment Researchs target price suggests a potential upside of 12.82% from the companys current price. []

Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA) Equities research analysts at Jefferies Financial Group increased their FY2021 earnings estimates for Ayala Pharmaceuticals in a research report issued to clients and investors on Tuesday, November 30th. Jefferies Financial Group analyst M. Raycroft now anticipates that the company will earn ($2.80) per share for the year, up from their []